Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC

NCT01947608 NO_LONGER_AVAILABLE

Novartis-sponsored, open-label, multi-center, interventional ETP to provide LDK378 to patients with ALK (+)NSCLC, who have been pre-treated with an ALK inhibitor; except in countries where ALK inhibitors are not approved or available. The protocol will further evaluate the safety of LDK378 in patients with ALK(+) NSCLC.

Details

Lead sponsor	Novartis Pharmaceuticals
Status	NO_LONGER_AVAILABLE

Conditions

• Non-small Cell Lung Cancer (NSCLC)

Interventions

• LDK378

Countries

Hong Kong, Colombia, Jordan, Mexico, Philippines, South Korea, Argentina, Thailand, United States, India